Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NYX-2925 in Healthy Volunteers (SAD/MAD)
NCT02834741Phase 1Completed
- Sponsor
- Aptinyx Inc.
- Start
- Jul 2016
- Primary completion
- Mar 2017
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NYX-2925 in diabetic peripheral neuropathy (DPN) and fibromyalgia (FM) (2 arms), sponsored by Aptinyx Inc. Primary endpoint: Number of subjects with adverse events at 30 days. Started Jul 2016; status: completed.
02
Drugs
NYX-2925
03
Conditions
diabetic peripheral neuropathy (DPN)fibromyalgia (FM)
Beyond the preview
Go deeper on NCT02834741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834741.